/Investors

Columbus Venture Partners

Venture capital

Valencia · Seed · 1 people tracked

Find your way into Columbus Venture Partners

256 people in our graph share verified history with the Columbus Venture Partners team — schools, employers, funds. One of them is your warm intro.

Montse Vendrellunlockedknows Jose Mesa · together at Peptomyc (overlapped)
knows the team · via Accipiter Biosciences
×5knows the team · via Alta Life Sciences
×5knows the team · via Caixa Capital Risc
✨ Fox Verdict
Sign up to see your fit

Investment thesis

Columbus Venture Partners focuses on life sciences and biotechnology, backing therapeutic and industrial products. The firm combines early-stage therapeutic seed investing with the creation of manufacturing infrastructure, seeking to build complete value chains and shorten timelines to return. It emphasizes designing exit routes before investing to maximize capital efficiency and highlights comparatively low management fees. Columbus describes itself as having one of the strongest track records in Spanish biotech venture, with an approach centered on developing life-changing therapies alongside solid financial performance in healthcare.

Source: firm website, verified Sep 27, 2026.

Stage
Seed
HQ
Valencia, ES
Leads rounds
Follows
Instruments
Equity
Last 12 months
2 investments
Tracked investments
39
IPOs
1
Acquisitions
2

Team · 1 people

from public directories

What they invest in

from 32 of 39 portfolio companies

Biotech ×23Healthtech ×19Medical Devices ×15Deep Tech ×13AI & Machine Learning ×7Advanced Manufacturing ×4Consumer ×2Digital Health ×2

HQs:United States×8Spain×7France×2European Union×1Netherlands×1

Investments · 39 tracked

founders shown can be your intro path

By year:2026 · 22025 · 12024 · 22023 · 12021 · 17 dated

Aura Biosciencesaurabiosciences.comin𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

PartnerJose Mesa· solo GP

Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxi+4 more

ARTHEx Biotech’s websitearthexbiotech.comin𝕏✓ verified

Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.

AI & Machine LearningBiotechMedical Devices

Beatriz Llamusí(Chief Scientific Officer & Co-Founder)in

PartnerJose Mesa· solo GP

Co-investorsBpifranceHadean VenturesSound BioventuresAdBio partnersInvivo Capital Partners

Quatrelabquatrelab.comin✓ verified

Quatre Lab is a Contract Research Organization specializing in quality control testing and validation of Advanced Therapy Medicinal Products (ATMPs) for biotech and pharmaceutical companies.

BiotechDeep TechHealthtechMedical DevicesSpain, ES

Patricia Muñoz(Managing Director)Columbus Venture Partners

PartnerJose Mesa· solo GP

Tyris TXtyristx.comin✓ verified

Tyris Therapeutics develops non-viral gene therapies using a proprietary DNA format (oDNA™) to treat rare and prevalent genetic diseases.

BiotechDeep TechHealthtechMedical DevicesValencia, ES

PartnerJose Mesa· solo GP

Vivet Therapeuticsvivet-therapeutics.comin𝕏✓ verified

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

PartnerJose Mesa· solo GP

Co-investorsHealthCapKurma PartnersNovartis Venture FundRoche Venture FundYsios CapitalEurazeo+1 more

Accipiter Biosciencesaccipiterbio.cominSeed · Jul 2026 · $13M

Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists.

AI & Machine LearningBiotechDeep TechSeattle, US

Matthew Bick(Executive Officer, Director, Promoter)inJavier Castellanos(Executive Officer, Director, Promoter)inHector De Jesus Rincon Arano(Executive Officer, Promoter)Heather Redman(Director)Randall Schatzman(Director)William Canestaro(Executive Officer)in

PartnerJose Mesa· solo GP

Co-investorsCreative Destruction Lab (CDL)Flying Fish VenturesArgonautic VenturesPack VenturesWRF Capital

Advantheraadvanthera.comin

Advanthera integrates regulatory guidance and clinical supply chain services to accelerate the development and manufacture of advanced therapies and innovative medicines.

AI & Machine LearningBiotechMedical Devices

Columbus Venture Partners

PartnerJose Mesa· solo GP

Aletabioaletabio.comin𝕏

Aleta Biotherapeutics develops multi-antigen CAR T Engager (CTE) biologics designed to improve the effectiveness of CAR T cell cancer therapies by increasing target antigen density and preventing cancer escape.

BiotechDeep TechHealthtech

PartnerJose Mesa· solo GP

Algenexalgenex.comin

Algenex develops proprietary baculovirus expression technologies and manufacturing processes for producing recombinant proteins used in pharmaceuticals and diagnostics.

Advanced ManufacturingBiotechDeep TechMedical Devices

PartnerJose Mesa· solo GP

Alto Pharmacyalto.comin𝕏

Alto Pharmacy is a full-service pharmacy that offers patients medication delivery, cost transparency, and pharmacist access.

ConsumerDigital HealthHealthtechSan Francisco, US

James Karraker(Executive Officer, Director)Mattieu Gamache-Asselin(Founder & CEO)inNichola Eliovits(Director)inNathaniel Kan(Director)Robert Spinner(Director)

BoardNeil Shah(Director)in

PartnerJose Mesa· solo GP

Co-investorsAvego BioScience CapitalBantam GroupCalm VenturesCSC UpshotEvolution VC PartnersFlucas Ventures+10 more

Artax Biopharmaartaxbiopharma.comin𝕏

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.

BiotechHealthtechCambridge, US

Damia Tormo(President, CEO, Treasurer and Founder)inJoe Suarez(Executive Officer)Maria Nichol(Executive Officer)inRobert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)in

BoardAndre Hoekema(Director)

PartnerJose Mesa· solo GP

Co-investorsSound BioventuresAdvent Life Sciences

AskBioaskbio.comin𝕏Acquired

AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease.

BiotechDeep TechHealthtechDurham, US

PartnerJose Mesa· solo GP

Co-investorsTPGVida Ventures

Cocoonbiosciencecocoonbioscience.comin

Cocoon Bioscience operates CrisBio, a recombinant protein expression platform that uses insects in a chrysalis (cocoon) state instead of traditional bioreactors to produce enzymes and complex proteins.

BiotechDeep TechNew Materials

PartnerJose Mesa· solo GP

Curapathcurapath.com

Curapath is a European Contract Development and Manufacturing Organization (CDMO) specializing in polymer- and lipid-based non-viral drug delivery systems for biotech and pharmaceutical companies.

Advanced ManufacturingBiotechDeep TechHealthtechMedical Devices

Philippe(Chief Executive Officer)Vicent(Chief Technology Officer)

PartnerJose Mesa· solo GP

Curve Therapeuticscurvetx.comin

Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.

AI & Machine LearningBiotech

PartnerJose Mesa· solo GP

Co-investorsEpidarex CapitalPfizer Venture Investments

Deepulldeepull.comin

Deepull develops a multiplex PCR diagnostic system to rapidly identify sepsis-causing pathogens and antibiotic resistance markers directly from blood samples in approximately one hour, targeting hospitals and clinical laboratories.

Medical Devices

Co-investorsAsabys PartnersAlta Life Sciences

Digitalsendadigitalsenda.comin

A digital agency offering design and development services—including 3D space configuration, digitizing physical samples into online catalogs, and ticket-sales platforms—for brands across multiple sectors.

Marketing TechSaaS

Highlight Therapeuticshighlighttherapeutics.comin

Highlight Therapeutics is a biotech company developing therapeutic treatments.

BiotechHealthtech

Marisol Quintero(Chief Operating Officer (former CEO 2013-2025))in

PartnerJose Mesa· solo GP

Co-investorsBuenavista Equity PartnersDroia Ventures

Integra Therapeuticsintegra-tx.com

PartnerJose Mesa· solo GP

Co-investorsAdBio partnersInvivo Capital Partners

Juratatfjuratatf.com

Jurata develops thermostable film-based formulations that allow vaccines and biologics to be stored and shipped without refrigeration and delivered without needles, including an intranasal film.

BiotechDeep TechHealthtechLogistics & Supply Chain

PartnerJose Mesa· solo GP

Larklark.comin𝕏Aug 2021

Lark develops an AI-powered health coaching platform that delivers personalized support for chronic disease prevention and management through 24/7 text-based conversations and integration with smart health devices.

AI & Machine LearningDigital HealthHealthtechMountain View, US

Julia Hu(Founder)in

PartnerJose Mesa· solo GP

Co-investorsAlpha Intelligence CapitalAsset Management CompanyCrunchFundIPD CapitalJoyance PartnersKing River Capital+8 more

Minoryx Therapeuticsminoryx.comin

Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.

BiotechDeep TechHealthtechMedical DevicesMataró, ES

Marc Martinell(Co-Founder & Chief Executive Officer)in

PartnerJose Mesa· solo GP

Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture Fund+5 more

Nerre Therapeuticsnerretherapeutics.com

PartnerJose Mesa· solo GP

Co-investorsAdvent Life SciencesFountain Healthcare PartnersOrbiMedForbionRedwood Ventures

Onaona.comin𝕏

Ona provides cloud-based agent infrastructure that runs developer tasks in isolated environments while laptops are closed, automating workflow execution through events, schedules, and pull requests.

AI & Machine LearningCloud ComputingDeveloper Tools

Co-investorsBright Pixel CapitalCrane Venture PartnersPebblebedPreston-Werner VenturesAlta Life SciencesAsabys Partners+4 more

ONAweareona.co

WE ARE ONA is a creative culinary studio that designs bespoke dining experiences for luxury and artistic brands, combining strategy, design, and production to reinforce emotional connections between brands and their audiences.

ConsumerFoodTechMarketplacesParis, FR

Luca Pronzato(Founder)

Co-investorsWind VentureKorysMérieux Equity PartnersYsios Capital

Ona Therapeuticsona-therapeutics.comin𝕏

Ona Therapeutics develops therapeutic antibodies targeting lipid metabolism to treat advanced and metastatic cancers, including liposarcoma.

BiotechHealthtechMedical Devices

Co-investorsAsabys PartnersFund+KorysMérieux Equity PartnersYsios CapitalAlta Life Sciences+2 more

Quibimquibim.comin𝕏Series A · Jan 2025 · $50M

Quibim develops cloud-based AI software platforms for medical imaging analysis that extract radiomics features and generate predictive models for healthcare providers and biopharma companies.

AI & Machine LearningHealthtechMedical Devices

PartnerJose Mesa· solo GP

Co-investorsAdara VenturesAmadeus Capital PartnersAPEX VenturesAsabys PartnersLifeX VenturesCambridge Innovation Capital+1 more

Quironsaludquironsalud.es

PartnerJose Mesa· solo GP

RECOVID Solutionsrecovidsolutions.com

PartnerJose Mesa· solo GP

Sanifitsanifit.comin𝕏

CSL is a biotechnology company that develops and manufactures plasma-derived and other therapies, including biotherapies for rare and serious diseases, vaccines, and treatments for iron deficiency and kidney disease.

BiotechHealthtechMedical Devices

Joan Perello Bestard(Founder)inCris Calsadain

Co-investorsAndera PartnersCriteria Bio VenturesInvivo Capital PartnersYsios Capital

Syngoisyngoi.comacquired by Artis BioSolutions

Artis BioSolutions is an integrated platform for genetic medicine that produces enzymatically synthesized synthetic DNA and develops it into clinical-grade advanced therapies with in-house GMP manufacturing.

Advanced ManufacturingBiotechMedical DevicesWatertown, US

PartnerJose Mesa· solo GP

Co-investorsAsahi Kasei Corporate Venture CapitalBuenavista Equity Partners

Taavtaav.comin

TAAV is a contract development and manufacturing organization (CDMO) that produces neDNA, an enzymatic DNA technology that serves as an alternative to plasmid DNA for manufacturing recombinant adeno-associated viruses (rAAV) used in gene therapy.

BiotechDeep TechHealthtechMedical DevicesSan Sebastian, ES

PartnerJose Mesa· solo GP

Tolerancetolerance.appOct 2024

Tolerance is a compliance platform that runs continuous automated checks against the NIST 800-171 standard and collects assessor-ready evidence for teams handling Controlled Unclassified Information (CUI).

CybersecurityGovTechSaaS

Co-investorsDorm RoomAmadeus Capital PartnersBen Franklin Technology PartnersBioAdvanceCriteria Bio VenturesEast Innovate+5 more

Tolerance Biotolerancebio.cominOct 2024

Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span.

BiotechDeep TechLongevityPhiladelphia, US

Francisco Leon(Executive Officer, Director)inPhilip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)in

BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)

Co-investorsBioAdvanceCriteria Bio VenturesBen Franklin Technology Partners

Viralgenviralgen.comin𝕏

Viralgen provides contract manufacturing services for AAV-based gene therapy, supporting early-phase preclinical and clinical production with a platform designed for regulatory compliance and batch scalability.

Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesSan Sebastián, ES

Jimmy Vanhove(CEO)

PartnerJose Mesa· solo GP

Visiumvisium.onein𝕏May 2026

Visium develops Far-UVC radiation-based sanitization devices and software to improve indoor air quality and reduce airborne pathogen transmission in occupied spaces.

CleantechHardwareHealthtechIoT

Stephen M. Ross(Co-Founder)Matt Higgins(Co-Founder, Chairman)John Rajchert(Co-Founder, CEO)in

Co-investorsRSE VenturesConcentric

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

ARTHEx BiotechRadioterapia de ProtonesViralgen Commercial

Exits · 3

1 IPOs · 2 acquisitions · showing 2

Aura BiosciencesNASDAQ: AURASyngoiacq. by Artis BioSolutions

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Columbus Venture Partners made?
Columbus Venture Partners has 39 tracked investments, 3 of which have exited, including 5 dated in the last 24 months.
What stage does Columbus Venture Partners invest at?
Columbus Venture Partners invests at the Seed stage.
What sectors does Columbus Venture Partners focus on?
Columbus Venture Partners focuses on Biotech, Healthtech, Longevity, Medical Devices.
Where is Columbus Venture Partners located?
Columbus Venture Partners is headquartered in Valencia, ES.
Does Columbus Venture Partners lead rounds?
Columbus Venture Partners typically participates in rounds rather than leading them.

Co-investors · 4

Ysios Capital

Ysios Capital is a life sciences venture investor that finances innovative biotech companies developing novel therapies for high unmet medical needs, primarily across Europe and the United States.

$5.4M – $21.6M
Advent Life Sciences

Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.

Both backed · 3
Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

Both backed · 2
$50K – $12.7M
Adara Ventures

Adara Ventures is an early-stage technology investor with roughly two decades of experience backing companies built on proprietary data, trust, domain depth and physical systems.

Both backed · 1
$540K – $7.6M

Firms observed investing alongside Columbus Venture Partners, from public investor directories. Shared companies are the overlap with Columbus Venture Partners's recorded portfolio.

Similar investors

Featured in lists